Vnitr Lek 2010, 56(12):1279-1285

Genetic background of adrenal cortex tumours - news

A. Kreze jr.1,*, P. Vaňuga2, M. Pura2
1 II. interní oddělení FN Na Bulovce Praha, přednosta prim. MUDr. Jiří Koskuba
2 Endokrinologické oddelenie Národného endokrinologického a diabetologického ústavu Ąubochňa, Slovenská republika, prednosta prim. MUDr. Peter Vaňuga, PhD.

This review has summarized the current knowledge of the genetic background of tumors originating from adrenocortical tissue, manifested as a part of inherited or familial syndromes, as well as specific forms of sporadic tumors caused by aberrant expression of G-protein coupled receptors.

Keywords: adrenal gland; tumor; genetics; genes; syndrome

Received: October 1, 2010; Published: December 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kreze A, Vaňuga P, Pura M. Genetic background of adrenal cortex tumours - news. Vnitr Lek. 2010;56(12):1279-1285.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658-5671. Go to original source... Go to PubMed...
    2. Koch CA, Pacak K, Chrousos GP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 2002; 87: 5367-5384. Go to original source... Go to PubMed...
    3. Langer P, Cupisti K, Bartsch DK et al. Adrenal involvement in multiple endocrine neoplasia type 1. World J Surg 2002; 26: 891-896. Go to original source... Go to PubMed...
    4. Ozawa A, Agarwal SK, Mateo CM et al. The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. J Clin Endocrinol Metab 2007; 92: 1948-1951. Go to original source... Go to PubMed...
    5. Pellegata NS, Quintanilla-Martinez L, Siggelkow H et al. Germ-line mutations in p27KiP1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 2006; 103: 15558-15563. Go to original source... Go to PubMed...
    6. Georgitsi M, Raitila A, Karhu A et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 2007; 92: 3321-3325. Go to original source... Go to PubMed...
    7. Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in MEN1 and related states. J Clin Endocrinol Metab 2009; 94: 1826-1834. Go to original source... Go to PubMed...
    8. Fritz A, Walch A, Piotrowska K et al. Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res 2002; 62: 3048-3051.
    9. Franklin DS, Godfrey VL, O'Brien DA et al. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol 2000; 20: 6147-6158. Go to original source... Go to PubMed...
    10. Falchetti A, Brandi ML. Multiple endocrine neoplasia type I variants and phenocopies: more than a nosological issue? J Clin Endocrinol Metab 2009; 94: 1518-1520. Go to original source... Go to PubMed...
    11. Carney JA, Gordon H, Carpenter PC et al. The complex of myxomas, spotty pigmentation and endocrine overactivity. Medicine (Baltimore) 1985; 64: 270-283. Go to original source... Go to PubMed...
    12. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001; 86: 4041-4046. Go to original source... Go to PubMed...
    13. Lytras A, Tolis G. Reproductive disturbances in multiple neuroendocrine tumor syndromes. Endocr Relat Cancer 2009; 16: 1125-1138. Go to original source... Go to PubMed...
    14. Marx SJ, Simonds WF. Hereditary hormone excess: genes, molecular pathways, and syndromes. Endocr Rev 2005; 26: 615-661. Go to original source... Go to PubMed...
    15. Stratakis CA, Boikos SA. Genetics of adrenal tumors associated with Cushing's syndrome: a new classification for bilateral adrenocortical hyperplasias. Nat Clin Pract Endocrinol Metab 2007; 3: 748-757. Go to original source... Go to PubMed...
    16. Stratakis CA. New genes and/or molecular pathways associated with adrenal hyperplasias and related adrenocortical tumors. Mol Cell Endocrinol 2009; 300: 152-157. Go to original source... Go to PubMed...
    17. Bourdeau I, Lacroix A. Abberant hormone receptors in adrenal Cushing's syndrome. Curr Opinion Endocrinol Diab 2002; 9: 230-236. Go to original source...
    18. Ye P, Mariniello B, Mantero F et al. G-protein-coupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism. J Endocrinol 2007; 195: 39-48. Go to original source... Go to PubMed...
    19. Zwermann O, Suttmann Y, Bidlingmaier M et al. Screening for membrane hormone receptor expression in primary aldosteronism. Eur J Endocrinol 2009; 160: 443-451. Go to original source... Go to PubMed...
    20. Sandrini F, Stratakis C. Clinical and molecular genetics of primary pigmented nodular adrenocortical disease. Arq Bras Endocrinol Metabol 2004; 48: 637-641. Go to original source... Go to PubMed...
    21. Horvath A, Bossis I, Giatzakis C et al. Large deletions of the PRKAR1A gene in Carney complex. Clin Cancer Res 2008; 14: 388-395. Go to original source... Go to PubMed...
    22. Sahut-Barnola I, de Joussineau C, Val P et al. Cushing's syndrome and fetal features resurgence in adrenal cortex-specific Prkar1a knockout mice. PLoS Genet 2010; 6: e1000980. Go to original source... Go to PubMed...
    23. Libé R, Fratticci A, Coste J et al. Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. Clin Cancer Res 2008; 14: 4016-4024. Go to original source... Go to PubMed...
    24. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966; 95: 1109-1119. Go to PubMed...
    25. Lifton RP, Dluhy RG, Powers M et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355: 262-265. Go to original source... Go to PubMed...
    26. Pizzolo F, Trabetti E, Guarini P et al. Glucocorticoid remediable aldosteronism (GRA) screening in hypertensive patients from a primary care setting. J Hum Hypertens 2005; 19: 325-327. Go to original source... Go to PubMed...
    27. Geller DS, Zhang JJ, Wisgerhof MV et al. A novel form of human Mendelian hypertension featuring non-glucocorticoid remediable aldosteronism. J Clin Endocrinol Metab 2008; 93: 3117-3123. Go to original source... Go to PubMed...
    28. Stowasser M, Gordon RD, Tunny TJ et al. Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clin Exp Pharmacol Physiol 1992; 19: 319-322. Go to original source... Go to PubMed...
    29. So A, Duffy DL, Gordon RD et al. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J Hypertens 2005; 23: 1477-1484. Go to original source... Go to PubMed...
    30. Jeske YW, So A, Kelemen L et al. Examination of chromosome 7p22 candidate genes RBaK, PMS2 and GNA12 in familial hyperaldosteronism type II. Clin Exp Pharmacol Physiol 2008; 35: 380-385. Go to original source... Go to PubMed...
    31. Goodarzi MO, Dawson DW, Li X et al. Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormone. J Clin Endocrinol Metab 2003; 88: 73-77. Go to original source... Go to PubMed...
    32. Christopoulos S, Bourdeau I, Lacroix A. Aberrant expression of hormone receptors in adrenal Cushing's syndrome. Pituitary 2004; 7: 225-235. Go to original source... Go to PubMed...
    33. Lacroix A, Ndiaye N, Tremblay J et al. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. Endocr Rev 2001; 22: 75-110. Go to original source...
    34. Lacroix A, Baldacchino V, Bourdeau I et al. Cushing's syndrome variants secondary to aberrant hormone receptors. Trends Endocrinol Metab 2004; 15: 375-382. Go to original source... Go to PubMed...
    35. Mazzuco TL, Chabre O, Feige JJ et al. Aberrant expression of human luteinizing hormone receptor by adrenocortical cells is sufficient to provoke both hyperplasia and Cushing's syndrome features. J Clin Endocrinol Metab 2006; 91: 196-203. Go to original source... Go to PubMed...
    36. Assie G, Louiset E, Sturm N et al. Systematic analysis of G protein-coupled receptor gene expression in adrenocorticotropin-independent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal Cushing's syndrome. J Clin Endocrinol Metab 2010; 95: E253-E262. Go to original source... Go to PubMed...
    37. Lefebvre H, Cartier D, Duparc C et al. Characterization of serotonin(4) receptors in adrenocortical aldosterone-producing adenomas: in vivo and in vitro studies. J Clin Endocrinol Metab 2002; 87: 1211-1216. Go to original source... Go to PubMed...
    38. Li S, Huang S, Peng SB. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol 2005; 27: 1329-1339. Go to original source...
    39. Saner-Amigh K, Mayhew BA, Mantero F et al. Elevated expression of luteinizing hormone receptor in aldosterone-producing adenomas. J Clin Endocrinol Metab 2006; 91: 1136-1142. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.